アブストラクト
| Title | 第6回 子どものメンタルヘルスにおける薬物療法 |
|---|---|
| Subtitle | 連載 児童精神科医が伝えたい 子どものメンタルヘルス |
| Authors | 宇佐美政英 |
| Authors (kana) | |
| Organization | 国立国際医療研究センター国府台病院子どものこころ総合診療センター長 / 児童精神科 診療科長 |
| Journal | 月刊薬事 |
| Volume | 62 |
| Number | 8 |
| Page | 1650-1658 |
| Year/Month | 2020 / 6 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | 「はじめに」わが国では, 2007年のメチルフェニデート徐放製剤 (methylphenidate-osmotic-controlled release oral delivery system ; MPH-OROS) の登場を皮切りに, アトモキセチン (atomoxetine ; ATX) , グアンファシン (guanfacine extended-release ; GXR) , リスペリドン (risperidone ; RSP) , アリピプラゾール (aripiprazole ; APZ) , フルボキサミン (fluvoxamine ; FVX) , そして最近ではリスデキサンフェタミン (lisdexamfetamine ; LDX) が, 児童精神科領域に適応のある薬剤として発売されてきました. しかしながら, 通常の臨床では子どものメンタルヘルスに対して薬物療法が早期から実施されることは皆無といってよいでしょう. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) McClellan J, et al: Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry, 52:976-990, 2013
- 2) Stafford MR, et al: Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: A systematic review and meta-analysis. PLoS One, 10:e0117166, 2015
- 3) Pandina GJ, et al: Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord, 37:367-373, 2007
- 4) Kent JM, et al: An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol, 23:676-686, 2013
- 5) ヤンセンファーマ株式会社:リスパダール,インタビューフォーム(2018年11月改訂,第18版)
残りの31件を表示する
- 6) Owen R, et al: Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124:1533-1540, 2009
- 7) 大塚製薬株式会社:エビリファイ,インタビューフォーム(2019年2月改訂,第23版)
- 8) Rey JM, et al: E.1 Depression in Children and Adolescents. JM Rey's IACAPAP: e-Textbook of Child and Adolescent Mental Health, 2015 (https://iacapap.org/english/)
- 9) 厚生労働省:NDBオープンデータ(https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177182.html)
- 10) 奥村泰之,他:日本における子どもへの向精神薬処方の経年変化;2002年から2010年の社会医療診療行為別調査の活用.精神神経学雑誌, 116:921-935, 2014
- 11) 宇佐美政英,他:児童・青年期におけるSSRI/SNRIの使用実態と安全性に関する全国調査.児童青年精神医学とその近接領域, 52:21-35, 2011
- 12) Comer JS, et al: National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry, 49:1001-1010, 2010
- 13) 牧野和紀,他:子どものADHDの診断・治療に関するエキスパート・コンセンサス:薬物療法編.児童青年精神医学とその近接領域, 56:822-855, 2015
- 14) Dalsgaard S: Attention-deficit/hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry, 22 (Suppl. 1):S43-S48, 2013
- 15) Zuddas A: Autism assessment tools in the transition from DSM-IV to DSM-5. Eur Child Adolesc Psychiatry, 22:325-327, 2013
- 16) Mikita N, et al: Mood dysregulation. Eur Child Adolesc Psychiatry, 22(Suppl. 1):S11-S16, 2013
- 17) 齊藤万比古:児童思春期精神障害(摂食障害を含む)の疾患概念と病態;発達危機という文脈での理解.精神神経学雑誌, 110:327-337, 2008
- 18) McCracken JT, et al: Risperidone in children with autism and serious behavioral problems. N Engl J Med, 347:314-321, 2002
- 19) Shea S, et al: Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114:e634-e641, 2004
- 20) Marcus RN, et al: Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol, 21:229-236, 2011
- 21) Kemner C, et al: Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psycho-pharmacol, 22:455-460, 2002
- 22) Stigler KA, et al: Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl). 223:237-245, 2012
- 23) Scahill L, et al: Weight gain and metabolic consequences of risperidone in young children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry, 55:415-423, 2016
- 24) Hollander E, et al: A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol, 16:541-548, 2006
- 25) Okumura Y, et al: Glucose and prolactin monitoring in children and adolescents initiating antipsychotic therapy. J Child Adolesc Psychopharmacol, 28:454-462, 2018
- 26) 厚生労働省「リスデキサンフェタミンメシル酸塩製剤の使用に当たっての留意事項について」(平成31年3月26日薬生総発0326第1号)
- 27) Charach A, et al: Childhood attention-deficit/hyperactivity disorder and future substance use disorders: Comparative meta-analyses. J Am Acad Child Adolesc Psychiatry, 50:9-21, 2011
- 28) Lee SS, et al: Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: A meta-analytic review. Clin Psychol Rev, 31:328-341, 2011
- 29) Singh I: Beyond polemics: science and ethics of ADHD. Nat Rev Neurosci, 9:957-964, 2008
- 30) Chang Z, et al: Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry, 55:878-885, 2014
- 31) Groenman AP, et al: Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. Br J Psychiatry, 203:112-119, 2013
- 32) McCabe SE, et al: Age of onset, duration, and type of medication therapy for attention-deficit/hyperactivity disorder and substance use during adolescence: A multi-cohort national study. J Am Acad Child Adolesc Psychiatry, 55:479-486, 2016
- 33) Storebo OJ, et al: Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents. JAMA, 315:2009-2010, 2016
- 34) Molina BS, et al: Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry, 52:250-263, 2013
- 35) Goldstein BI: Do stimulants prevent substance use and misuse among youth with attention-deficit/hyperactivity disorder? The Answer Is Still Maybe. J Am Acad Child Adolesc Psychiatry, 52:225-227, 2013
- 36) Shaw P: Quantifying the benefits and risks of methylphenidate as treatment for childhood attention-deficit/hyperactivity disorder. JAMA, 315:1953-1955, 2016
